3 Medical Info Systems Stocks Riding the GenAI Wave in a Tough Market

Why It Matters

AI‑driven efficiency and remote‑care tools are reshaping hospital economics, making the sector a high‑growth, yet risk‑laden, investment theme for investors seeking exposure to digital health transformation.

Key Takeaways

• AI in healthcare projected 38.6% CAGR through 2030.
• Smart healthcare market to reach $485.7B by 2032.
• Omnicell, Veeva, Doximity hold top Zacks ranks in sector.
• Industry P/S ratio 3.47×, below S&P 500’s 5.21×.
• Cyber attacks hit healthcare 642 incidents in 2025, 460 ransomware.

Pulse Analysis

Generative AI is moving from pilot projects to core infrastructure in electronic health records, diagnostics and workflow automation. Clinicians now rely on AI copilots for real‑time documentation, reducing burnout and improving decision support. This shift fuels the AI‑in‑healthcare market’s aggressive 38.6% compound annual growth rate, while investors watch the broader smart‑healthcare ecosystem expand toward a $485.7 billion valuation by 2032, driven by wearables, telehealth and interoperable data platforms.

Omnicell, Veeva Systems and Doximity stand out as the sector’s most compelling picks. Omnicell’s automation suite targets medication safety and cost control, earning a Zacks #1 Strong Buy and a 22.2% earnings outlook for 2026. Veeva leverages its life‑sciences cloud to deepen R&D and regulatory solutions, with an 8.8% earnings boost expected for fiscal 2027. Doximity, covering over 85% of U.S. physicians, monetizes through subscription and pharma‑targeted services, projecting an 8.5% earnings rise in fiscal 2026. All three enjoy strong Zacks rankings, underscoring their near‑term momentum.

Despite growth, the industry faces mounting headwinds. Cybersecurity incidents surged to 642 healthcare breaches in 2025, including 460 ransomware attacks, exposing patient data and disrupting operations. Regulatory bodies are tightening AI governance, demanding transparency and bias mitigation, which could slow deployment timelines. Valuation remains modest at a 3.47× forward price‑to‑sales multiple, offering a discount to the broader S&P 500 but signaling investor caution. Balancing the upside of AI‑enabled efficiency against security and compliance risks will be key for stakeholders navigating this evolving market.